Reinhold Mueller

USPTO Granted Patents = 13 (Patent Applications = 5)

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 102(Granted Patents)

Company Filing History:

Abb Vie Deutschland Gmbh & Co. Kg

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2004-2019

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10464976 - Amyloid β(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof (2019-11-05),

2. 10040852 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof (2018-08-07),

3. 9394363 - Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof (2016-07-19),

4. 9255146 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) and uses thereof (2016-02-09),

5. 9176150 - Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof (2015-11-03),

6. 8906864 - Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use (2014-12-09),

7. 8323651 - Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof (2012-12-04),

8. 7906120 - Neutralizing monoclonal antibodies against the Nogo-66 receptor (NgR) (2011-03-15),

9. 7491729 - 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof (2009-02-17),

10. 7041675 - Heterocyclic compounds and their use as PARP inhibitors (2006-05-09),

11. 7026311 - Dibenzodiazepine derivatives, their preparation and use (2006-04-11),

12. 6737421 - Cyclo-alkyl substituted benzimidazoles and their use as PARP inhibitors (2004-05-18),

13. 6696437 - Heterocyclically substituted benzimidazoles, the production and application thereof (2004-02-24),

Title: Reinhold Mueller: Innovator in Neuromodulatory Applications

Introduction

Reinhold Mueller, an accomplished inventor based in Schifferstadt, Germany, has made significant strides in the field of biomedical research. With a remarkable portfolio consisting of 13 patents, his contributions have been pivotal, particularly in the development of therapeutic and diagnostic agents related to neurological disorders.

Latest Patents

Among his latest inventions are two notable patents focusing on amyloid-β(1-42) oligomers and monoclonal antibodies against the Nogo-66 receptor (NgR). The first patent describes a method for producing neuromodulatory oligomers derived from the amyloid-β(1-42) protein. This innovative process yields high quantities of oligomers that can be utilized as diagnostic and therapeutic agents. Moreover, it aids in generating oligomer-specific antibodies and discovering substances that interact with these oligomers.

The second patent presents isolated monoclonal antibodies targeting the Nogo-66 receptor, which play a crucial role in inhibiting its activity. These antibodies are instrumental in detecting NgR and mitigating its detrimental effects in conditions where NgR or Nogo-66 activity is harmful.

Career Highlights

Reinhold Mueller has had an impactful career, notably working with companies such as Abbott GmbH & Co. KG and AbbVie Deutschland GmbH & Co. KG. His experience in these prestigious organizations has allowed him to further his research and development efforts in the biomedical sector, blending innovation with practical applications in healthcare.

Collaborations

Throughout his career, Reinhold has collaborated with esteemed colleagues like Martin Schmidt and Achim Moeller. These partnerships have fostered a rich environment for creativity and led to the successful exploration of various biomedical innovations.

Conclusion

Reinhold Mueller stands out as a prolific inventor whose work is shaping the future of neuromodulatory therapies. With an impressive list of patents and collaborations, his ongoing contributions are expected to continue influencing the fields of diagnostics and therapeutics in neurology.

This text is generated by artificial intelligence and may not be accurate.